GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » China Resources Double-Crane Pharmaceutical Co Ltd (SHSE:600062) » Definitions » Equity-to-Asset

China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Equity-to-Asset : 0.73 (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is China Resources Double-Crane Pharmaceutical Co Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. China Resources Double-Crane Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Mar. 2024 was ¥11,516 Mil. China Resources Double-Crane Pharmaceutical Co's Total Assets for the quarter that ended in Mar. 2024 was ¥15,679 Mil. Therefore, China Resources Double-Crane Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 was 0.73.

The historical rank and industry rank for China Resources Double-Crane Pharmaceutical Co's Equity-to-Asset or its related term are showing as below:

SHSE:600062' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.67   Med: 0.76   Max: 0.89
Current: 0.73

During the past 13 years, the highest Equity to Asset Ratio of China Resources Double-Crane Pharmaceutical Co was 0.89. The lowest was 0.67. And the median was 0.76.

SHSE:600062's Equity-to-Asset is ranked better than
72.06% of 1088 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs SHSE:600062: 0.73

China Resources Double-Crane Pharmaceutical Co Equity-to-Asset Historical Data

The historical data trend for China Resources Double-Crane Pharmaceutical Co's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Resources Double-Crane Pharmaceutical Co Equity-to-Asset Chart

China Resources Double-Crane Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Equity-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.76 0.74 0.72 0.70 0.72

China Resources Double-Crane Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Equity-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.71 0.70 0.72 0.72 0.73

Competitive Comparison of China Resources Double-Crane Pharmaceutical Co's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, China Resources Double-Crane Pharmaceutical Co's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


China Resources Double-Crane Pharmaceutical Co's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, China Resources Double-Crane Pharmaceutical Co's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where China Resources Double-Crane Pharmaceutical Co's Equity-to-Asset falls into.



China Resources Double-Crane Pharmaceutical Co Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

China Resources Double-Crane Pharmaceutical Co's Equity to Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Equity to Asset (A: Dec. 2023 )=Total Stockholders Equity/Total Assets
=11090.411/15430.96
=0.72

China Resources Double-Crane Pharmaceutical Co's Equity to Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

Equity to Asset (Q: Mar. 2024 )=Total Stockholders Equity/Total Assets
=11515.833/15679.094
=0.73

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


China Resources Double-Crane Pharmaceutical Co  (SHSE:600062) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


China Resources Double-Crane Pharmaceutical Co Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of China Resources Double-Crane Pharmaceutical Co's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Business Description

Traded in Other Exchanges
N/A
Address
No. 1, East Second Road, Lijing, Wangjing, Chaoyang District, Beijing, CHN, 100102
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.

China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Headlines

No Headlines